Strange trading..
Depth at 50 was pretty solid last week, but very weak now.
Hoping for a strong Q1 report to bring back some confidence.
No doubt COVID has slowed progression with Bioplate in the US.
Given the strong cash position ($9M) and low burn ($1M per quarter) there is still a minimum 12month run way before any further raises.
Plenty of time for the recent distribution deals in the US, Germany, Austria, Australia & New Zealand to finish product training and get some market penetration.
Ex ResMed CFO, Carl is also looking after Investor Relations so we may get some decent exposure to drum up some hype.
Add to My Watchlist
What is My Watchlist?
